Anti-D Alloimmunization Following Rhesus-Incompatible Platelet Transfusion in a Myelodysplastic Syndrome Patient.

Autor:	Hanafi R; Department of Ophthalmology and Visual Science, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, MYS.; Faculty of Medicine, Universiti Sultan Zainal Abidin (UniSZA), Kuala Terengganu, MYS., Zulkeflee RH; Department of Hematology, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, MYS., Hassan MN; Department of Hematology, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, MYS., Saidin NIS; Department of Hematology, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, MYS., Adzahar S; Department of Pathology, Faculty of Medicine, Universiti Sultan Zainal Abidin (UniSZA), Kuala Terengganu, MYS., Hassan R; Department of Hematology, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, MYS.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Mar 29; Vol. 16 (3), pp. e57165. Date of Electronic Publication: 2024 Mar 29 (Print Publication: 2024).
DOI:	10.7759/cureus.57165
Abstrakt:	Patients with myelodysplastic syndrome (MDS) often need platelet transfusions to address thrombocytopenia. The risk of alloimmunization, particularly in Rhesus (Rh) incompatibility between donors and recipients during platelet transfusions, is heightened, especially with whole blood-derived pooled platelets as opposed to apheresis platelets. Although the occurrence of alloimmunization from platelet transfusions is minimal, there is an ongoing debate about whether Rh immune globulin (RhIg) should be administered to Rhesus D (RhD)-negative recipients of RhD-positive platelet units. We present a unique case of anti-D alloimmunization in a 56-year-old patient with underlying MDS following multiple platelet transfusions but never received packed cell transfusion or anti-D immunoglobulin. Some studies advocate for RhIg administration in specific scenarios and for certain patient populations. This case underscores the importance of considering Rhesus compatibility or administering anti-D immunoglobulin in cases where frequent platelet transfusions are required. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Hanafi et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu